OsteoarthritisNCT06573502
Platelet Rich Plasma Combined With Platelet Rich Fibrin in Management of Temporomandibular Joint Osteoarthritis
A study testing Prp with prf or prp or prf in people with Osteoarthritis, run by Aliaa Babekir Ahmed Mohamed at 1 site in Egypt.
Trial summary
Studying effectiveness of prp with prf comparing with prp or prf for mangement of tmj osteoarthritis as result in pain and mandibular movement in adult pt Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Osteoarthritis
- What is being tested?
- Prp with prf or prp or prf
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 42 participants
- Where
- 1 siteEgypt
- Study dates
- 29 Mar 2025to 16 Nov 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Adult pt with OA
Who cannot join
- Medicaly compromised
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Assessment of Platelet Rich Plasma With Injectable Platelet Rich Fibrin VS Platelet Rich Plasma Vs Platelet Rich Fibrin in Management of Temporomandibular Joint Osteoarthritis
Studying effectiveness of prp with prf comparing with prp or prf for mangement of tmj osteoarthritis as result in pain and mandibular movement in adult pt
Read the detailed description
45 pt assigned for the study , divided in to three gruops to comparing new combination of prp with prf in management of TMJ OA
- Conditions
- Osteoarthritis
- Being tested
- Prp with prf or prp or prf
- Medical subject headings
- Osteoarthritis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Prp with prf or prp or prfCombination product
Combination
| Study group | Role | What they receive |
|---|---|---|
| prp with prf group | Experimental | Pt will recievd prp with prf Receives: Combination Product: Prp with prf or prp or prf |
| prp group | Active comparator | Pt will recieve prp only Receives: Combination Product: Prp with prf or prp or prf |
| prf group | Experimental | Pt will recieve prf only Receives: Combination Product: Prp with prf or prp or prf |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pain severty
Visual analog scale measure for pain most sever pain take 10 minimum pain take 0
Measured: 6 months
Secondary outcomes (1)
Maximum mouth opening
Measured with calipar
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Aug 2024
- Study start29 Mar 2025
- Primary completion29 Sep 2025
- Study completion16 Nov 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for OsteoarthritisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 42 participants (actual)
Sponsor and investigators
- Lead sponsor
- Aliaa Babekir Ahmed Mohamed
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Aliaa Babekir Ahmed Mohamed, Cairo University
- Investigators
- Hassan Ab Ghany, Prof, Study director, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06573502
- Sponsor's protocol ID
- Not selected
- Status last verified
- Dec 2025
- First submitted
- 31 Jul 2024
- Last updated
- 12 Dec 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of Platelet Rich Plasma With Injectable Platelet Rich Fibrin VS Platelet Rich Plasma Vs Platelet Rich Fibrin in Management of Temporomandibular Joint Osteoarthritis
- ClinicalTrials.gov ID
- NCT06573502
- Acronym / sponsor ID
- Not selected
- Conditions
- Osteoarthritis
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 42 participants (actual)
- Lead sponsor
- Aliaa Babekir Ahmed MohamedUniversity, hospital or other
- Study start
- 29 Mar 2025 (actual)
- Primary completion
- 29 Sep 2025 (actual)
- Study completion
- 16 Nov 2025 (actual)
- First posted
- 27 Aug 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Studying effectiveness of prp with prf comparing with prp or prf for mangement of tmj osteoarthritis as result in pain and mandibular movement in adult pt
Detailed description
45 pt assigned for the study , divided in to three gruops to comparing new combination of prp with prf in management of TMJ OA
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| prp with prf group | Experimental | Combination Product: Prp with prf or prp or prfPt will recievd prp with prf |
| prp group | Active comparator | Combination Product: Prp with prf or prp or prfPt will recieve prp only |
| prf group | Experimental | Combination Product: Prp with prf or prp or prfPt will recieve prf only |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- Adult pt with OA
Key exclusion criteria (1 listed)
- Medicaly compromised
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Prp with prf or prp or prfCombination | Combination product | prf group, prp group, prp with prf group |
Primary outcome
Pain severty
Time frame: 6 months
Visual analog scale measure for pain most sever pain take 10 minimum pain take 0
1 secondary outcome
Maximum mouth opening
Time frame: 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Dec 2025.
- Individual participant dataSharing planned: No
Related trials for Osteoarthritis
Recruiting
Effect of Anti-inflammatory Diet in Osteoarthritis
Osteoarthritis, Knee
Active, not recruiting
Effectiveness of Therapeutic Exercises on Spinopelvic Mobility
Osteoarthritis (OA) of the Hip
Active, not recruitingPhase 2/3
Single vs Triple Hyaluronic Acid in Knee Osteoarthritis
Osteoarthritis, Knee
Not yet recruiting
Holistic Healing for Knee Osteoarthritis
Knee Osteoarthritis (Knee OA)
RecruitingObservational study
Exploring Factors Linked to Worsening Over Time in People With Early-stage Knee Osteoarthritis and Those With Prior Proven Acute Knee Injury.
Knee Osteoarthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hassan Ab Ghany, Prof study director
Cairo University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Prp with prf or prp or prf in people with Osteoarthritis, run by Aliaa Babekir Ahmed Mohamed at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pain severty (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Dec 2025; AzTrials last refreshed its copy on 8 Nov 2026.